ANSPOR Drug Patent Profile
✉ Email this page to a colleague
When do Anspor patents expire, and when can generic versions of Anspor launch?
Anspor is a drug marketed by Glaxosmithkline and is included in two NDAs.
The generic ingredient in ANSPOR is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ANSPOR?
- What are the global sales for ANSPOR?
- What is Average Wholesale Price for ANSPOR?
Summary for ANSPOR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 74 |
| Patent Applications: | 4,762 |
| DailyMed Link: | ANSPOR at DailyMed |
US Patents and Regulatory Information for ANSPOR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ANSPOR | cephradine | CAPSULE;ORAL | 061859-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | ANSPOR | cephradine | FOR SUSPENSION;ORAL | 061866-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | ANSPOR | cephradine | CAPSULE;ORAL | 061859-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Glaxosmithkline | ANSPOR | cephradine | FOR SUSPENSION;ORAL | 061866-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
